These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 37545521)

  • 1. Comprehensive analysis and immune landscape of chemokines- and chemokine receptors-based signature in hepatocellular carcinoma.
    Zhang Z; Mao M; Wang F; Zhang Y; Shi J; Chang L; Wu X; Zhang Z; Xu P; Lu S
    Front Immunol; 2023; 14():1164669. PubMed ID: 37545521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
    Gao S; Zhang L; Wang H
    Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment.
    Wei S; Tan J; Huang X; Zhuang K; Qiu W; Chen M; Ye X; Wu M
    J Transl Med; 2024 Jul; 22(1):711. PubMed ID: 39085893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
    Yan Z; He M; He L; Wei L; Zhang Y
    Front Immunol; 2021; 12():723271. PubMed ID: 34925311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
    Ren M; Fan B; Cao G; Zong R; Feng L; Sun H
    BMC Genomics; 2023 Dec; 24(1):776. PubMed ID: 38097948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
    Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
    Front Immunol; 2022; 13():994019. PubMed ID: 36177006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
    Xiao Y; Li J; Wu J
    BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
    Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
    J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
    Wang S; Gao S; Shan L; Qian X; Luan J; Lv X
    PeerJ; 2023; 11():e14691. PubMed ID: 36650832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
    Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
    Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
    Liu R; Liu Y; Zhang F; Wei J; Wu L
    Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma.
    Wang Y; Song F; Zhang X; Yang C
    Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis
    Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J
    Front Immunol; 2023; 14():1137025. PubMed ID: 37006257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
    Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
    Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma.
    Chen J; Wang H; Zhou L; Liu Z; Chen H; Tan X
    Cancer Med; 2022 Dec; 11(24):5079-5096. PubMed ID: 35560794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
    Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
    Front Immunol; 2022; 13():990790. PubMed ID: 36248822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
    Gao B; Wang Y; Lu S
    Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.